Roche Holding AG

Roche Holding AG

Roche Holding AG

Overview
Date Founded

1966

Headquarters

Grenzacherstrasse 124,Basel, Basel-Stadt (Basle Town) 4070

Type of Company

Public

Employees (Worldwide)

94.4K

Industries

Pharmaceuticals
Wholesale: Consumer Non-Durables/Sundries
IT Consulting & Services
Holding Companies
Medical Support Services
Biotechnology

Company Description

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

Contact Data
Trying to get in touch with decision makers at Roche Holding AG? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer

Chief Financial & Information Technology Officer

General Counsel

Chairman & Chief Executive Officer of Chugai

Secretary-Executive Committee & Head-Chief Executive Officer Office

Head of Group Communications

Member of the Enlarged Corporate Executive Committee, Global Head Pharma Partnering

Global Head, Neurodegeneration

Chief Medical Officer & Head of Global Product Development

Head-Cancer Immunotherapy Discovery

Board of Directors

Honorary Professor at University of St. Gallen

Treasurer & Director at Fondation Auxiliaire du Conservatoire botanique de la Ville de

Chief Executive Officer at Roche Holding AG

Former Senior Physician, Orthopedic Hospital at University of Basel

Manager at ESCP Europe Campus Paris

President & Director at The Rockefeller University

Venture Partner at LSP Management Group BV

Executive Director, Chief Financial Officer & Chief Operating Officer at Burberry Group Plc

External Senior Adviser at McKinsey & Co., Inc.

Paths to Roche Holding AG
Potential Connections via
Relationship Science
You
Roche Holding AG
Owners & Shareholders
Details Hidden

Dodge & Cox's investment decisions are made by a team of seasoned investment professionals based on key fundamental factors that they believe determine investment value over the long term. The firm's investment analysts operate from a single location to foster communication and collaboration and each investment idea is subject to committee review for both its merits as a specific investment and its role in the overall portfolio. Their approach stresses an evaluation of risk relative to opportunity and we seek investments that we believe are undervalued by the market. Fundamental bottom-up research, a rigorous valuation discipline and a long-term investment horizon are central to Dodge & Cox's investment philosophy.

Details Hidden

DI is an active, value-oriented manager which manages portfolios primarily with a mid-to long-term focus. They invest in global debt and equity across sectors and market-caps including Euro zone equity, Spanish equity, US equity, Euro zone fixed-income, US fixed-income, Japanese fixed-income, Latin American fixed-income, emerging markets fixed-income and Canadian fixed-income.

Details Hidden

Banque Morval is a conservative manager which focuses on long-term capital preservation, tailoring their investment approach to client profiles. Their investment philosophy consists of balancing absolute return and risk, especially in volatile markets such as emerging countries. Their geographic focus is global.The bank invests in equity and fixed-income, aiming to limit risk by diversifying across asset classes, sectors and geographic regions. They have specialist expertise in international equity value-style investments and emerging market equity. In emerging markets, the bank invests across a region in a variety of countries to hedge risks. They have a relatively high tolerance for short-term volatility.Banque Morval manages a series of regional funds invested globally in equity, debt and money market instruments, as well as a telecom sector fund. Their funds are used as building blocks in the management of client portfolios within the Morval Group and by third-party intermediaries.

Recent Transactions
Details Hidden

Fuji Chemical Industries Ltd. purchases Chugai Pharmaceutical Co. Ltd. /Ulcerlmin Bus from Roche Holding AG

Details Hidden

Roche Holding AG purchases Spark Therapeutics, Inc.

Details Hidden

Genentech, Inc., Roche Holding AG purchase Jecure Therapeutics, Inc. from Versant Venture Management LLC

Transaction Advisors
Legal Advisor

Advised onRoche Holding AG purchases Genentech, Inc.

Investment Advisor

Advised onKoninklijke DSM NV purchases Roche Holding AG /Roche Vitamins Unit from Roche Holding AG

Investment Advisor

Advised onRoche Holding AG purchases InterMune, Inc.

Legal Advisor

Advised onRoche Holding AG purchases InterMune, Inc.

Legal Advisor

Advised onRoche Holding AG purchases InterMune, Inc.

Legal Advisor

Advised onRoche Holding AG purchases Genentech, Inc.

Advisors & Consultants
Advisor

Executive Vice President & Chief Investment Officer at Connecticut Innovations, Inc.

Advisor

Founder at Lassiter Consulting

Legal Advisor

Partner at Orrick, Herrington & Sutcliffe LLP

Clients

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. Its two main products are Ampyra and Zanaflex Capsules. The Ampyra is an oral drug, which treats to improve walking in patients with multiple sclerosis and Zanaflex Capsules, which is a short acting drug for the management of spasticity, a symptom of many central nervous system disorders, including multiple sclerosis and spinal cord injury. The company was founded by Ronald Cohen in 1995 and is headquartered in Ardsley, NY.

Cipla Ltd. engages in the manufacture and distribution of healthcare products and bulk drugs. It operates through the Pharmaceuticals and New Ventures segments. The Pharmaceuticals segment develops, manufactures, sells and distributes generic or branded generic medicines as well as active pharmaceutical ingredients. The New Ventures segment includes the operations of the two wholly owned subsidiaries, Cipla Health Ltd., a consumer healthcare company and Cipla BioTec Pvt. Ltd, which is into the business of Biosimilars. The company was founded by Khwaja Abdul Hamied in 1935 and is headquartered in Mumbai, India.

Key Stats and Financials As of 2018
Market Capitalization
$220B
Total Enterprise Value
$218B
Earnings Per Share
$12.3
Revenue
$56.8B
Net Profit
$10.5B
EBITDA
$20.3B
EBITDAMargin
35.73%
Total Debt
$18.8B
Total Equity
$30.4B
Enterprise Value Sales
3.83x
Enterprise Value EBITDAOperating
10.71x
TEVNet Income
20.72x
Debt TEV
0.09x
Three Year Compounded Annual Growth Rate Of Revenue
5.69%
Five Year Compounded Annual Growth Rate Of Revenue
3.97%
Investments
Details Hidden

Vaccibody AS reates vaccines and immunotherapy. Its Vaccibody Vaccine Platform Technology is use for the variety of disease models including infectious diseases and cancer. The firm offers preclinical data for Vaccines against Human Papilloma Virus induced Cancer, Melanoma, Prostate Cancer, B Cell Lymphoma, and Multiple Myeloma showing the platform's ability to induce T cell responses and to eliminate cancer cells. Its therapeutic vaccines offer low-toxicity treatment options for early stage disease and enhance the efficacy of existing regimens in late-stage disease while adding minimal toxicity. The company was founded by Inger Sandlie on November 22, 2006 and is headquartered in Oslo, Norway.

Details Hidden

Eloxx Pharmaceuticals Ltd. provides biopharmaceutical research and development services. The firm specializes in the discovery, development, and commercialization of drug compounds for the treatment of genetic diseases. It focuses on the treatment of diseases caused by nonsense mutations, including Cystic fibrosis, Duchene Muscular Dystrophy, Usher syndrome, Ataxia-telangiectasia, Beta thalassemia, and Tay-Sachs Hurler syndrome. Its focus areas encompass clinical drug development and target drugs discovery programs. The company was founded by Silvia Noiman and Shmuel Tuvia in 2013 and is headquartered in Herzliya, Israel.

Details Hidden

cCAM Biotherapeutics Ltd. engages in the development of immunotherapies for different cancer indications. Its cCAM's lead agent, CM-24, is an immunomodulatory antibody that harnesses the patient's immune system to attack tumors. The company was founded in 2010 and is headquartered in Misgav, Israel.

Investors
Details Hidden

Founder at Streamlined Ventures LLC

Details Hidden

Professional at Genentech, Inc.

Details Hidden

Advisor at Qwiki, Inc.

Suppliers
Alexandria Real Estate Equities, Inc. Real Estate Investment Trusts | Pasadena, CA

Alexandria Real Estate Equities, Inc. is an urban office real estate investment trust, which engages in the ownership, operation, development, and redevelopment of life science and technology properties. It also provides a space for lease to the life science and technology industries which are primarily located in AAA urban innovation cluster locations. The company was founded by Alan D. Gold, Gary A. Kreitzer, Joel S. Marcus, and Jerry M. Sudarsky in October 1994 and is headquartered in Pasadena, CA.

Xenon Pharmaceuticals, Inc. Pharmaceuticals | Burnaby, BC

Xenon Pharmaceuticals, Inc. engages in discovering and developing therapeutics to improve the lives of patients with neurological disorders. It focuses on the treatment of epilepsy. Its products include XEN496, XEN1101, XEN901, and XEN007. The company was founded by Simon Neil Pimstone, Johannes J. P. Kastelein, and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.

Exelixis, Inc. Biotechnology | SOUTH SAN FRANCISCO, CA

Exelixis is a biopharmaceutical company committed to developing and commercializing small molecule therapies for the treatment of cancer. In advancing our first product, COMETRIQ, from discovery to market, we have established an effective and integrated infrastructure that encompasses the entire biopharmaceutical development continuum. We are committed to excellence in all aspects of our work and are dedicated to improving the care and outcome of cancer patients.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Roche Holding AG. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Roche Holding AG's profile does not indicate a business or promotional relationship of any kind between RelSci and Roche Holding AG.
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/organization/roche-holding-ag-13721
  • https://relationshipscience.com/organization/roche-holding-ag-13721